STOCK TITAN
  1. Home
  2. Sec-filings
  3. LYRA
  4. [S-1] Lyra Therapeutics, Inc. Files IPO Registration Statement

[S-1] Lyra Therapeutics, Inc. Files IPO Registration Statement

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
S-1

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock LYRA logo
Lyra Therapeutics, Inc.

NASDAQ:LYRA

LYRA Rankings

#6129 Ranked by Market Cap
N/A Ranked by Dividends

LYRA Latest News

Aug 12, 2025
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jun 27, 2025
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Jun 2, 2025
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
May 7, 2025
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
May 6, 2025
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

LYRA Latest SEC Filings

Oct 3, 2025
[Form 4] Lyra Therapeutics, Inc. Insider Trading Activity
Sep 4, 2025
[8-K] Lyra Therapeutics, Inc. Reports Material Event
Aug 22, 2025
[8-K] Lyra Therapeutics, Inc. Reports Material Event
Aug 14, 2025
[SCHEDULE 13D/A] Lyra Therapeutics, Inc. SEC Filing
Aug 12, 2025
[10-Q] Lyra Therapeutics, Inc. Quarterly Earnings Report

LYRA Stock Data

11.51M
1.38M
0.67%
38.13%
2.77%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States
WATERTOWN